Specialty Areas: ARDS, lung infection
Chronology: BA: Harvard College (1998); PhD: Massachusetts Institute of Technology (2005); MD: Harvard Medical School (2007); Internship: Johns Hopkins University School of Medicine (2007-2008); Residency: Johns Hopkins University School of Medicine (2008-2010); PCCM Fellowship: Johns Hopkins University School of Medicine (2010-2014)
Dr. Hagan’s lab studies host defense mechanisms in respiratory infections, with a focus on macrophage signaling pathways in influenza infection. We use a combination of mouse genetics, cell biology, and protein biochemistry to understand how macrophages contribute to both pathogen control and tissue damage.
Hagan RS, Collins SL, Chornoguz O, Patel CH, Horton MR, Powell JD. mTORC1 is required for TBK1 activation in macrophages and lymphocytes. In preparation
Waickman AT, Drake R, Hagan RS, Pollizzi KN, Patel CH, Powell JD. Inhibition of mTORC1 enhances IL-9 production and Th9 differentiation via the transcription factor TFEB. In revision, J Immunology
Black KE, Collins SL, Hagan RS, Hamblin MJ, Chan-Li Y, Hallowell RW, Powell JD, Horton MR. Hyaluronan fragments induce IFNbeta via a novel TLR4-TRIF-TBK1-IRF3-dependent pathway. J Inflamm (Lond). 2013 May 30; 10(1):23.
Hagan RS, Manak MS, Buch HK, Meier MG, Meraldi P, Shah JV, Sorger PK. p31(comet) acts to ensure timely spindle checkpoint silencing subsequent to kinetochore attachment. Mol Biol Cell. 2011 Nov;22(22):4236-46.
Hagan RS, Powell JD. Targeted immunosuppression: No longer naïve. Clin Immunol. 2012 Feb; 142(2):95-6.
Mapelli M, Fillip FV, Rancati G, Massimiliano L, Nezi L, Stier G, Hagan RS, Confalonieri S, Piatti S, Sattler M, Musacchio A. Determinants of conformational dimerization of Mad2 and its inhibition by p31comet. EMBO J. 2006 Mar 22;25(6):1273-84.
Hagan RS and Sorger PK. The more MAD, the merrier. Nature. 2005 Mar 31; 434(7033):575-7.